Sanofi (NYSE:SNY) is one of the globe's largest drug companies. It's a major player in diabetes treatments, vaccines, and consumer medicines, and is often included in dividend portfolios.
However, looming patent expiration on its top-selling drug, falling margin, and potential competition from Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) could all impact Sanofi's bottom line, and threaten Sanofi's dividend.
In the following slideshow, you'll learn whether I think Sanofi's dividend is safe, and see how Sanofi's dividend matches up to Lilly and Novo Nordisk.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC, Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.